# Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

> **NCT04827563** · — · TERMINATED · sponsor: **University of Chicago** · enrollment: 50 (actual)

## Conditions studied

- Multiple Myeloma
- Shortness of Breath
- Dyspnea
- Cardiotoxicity

## Interventions

- **DEVICE:** EndoPAT
- **DEVICE:** Blood Pressure Cuff
- **DIAGNOSTIC_TEST:** Echocardiogram
- **OTHER:** Quality of Life Assessment
- **OTHER:** Blood Tests

## Key facts

- **NCT ID:** NCT04827563
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-22
- **Primary completion:** 2025-09-08
- **Final completion:** 2025-09-08
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Study terminated by PI
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827563, "Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04827563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*